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Abstract
Heart Rate Variability (HRV) represents cardiac autonomic behavior and have been related
to menopausal symptoms, mainly vasomotor symptoms and their imbalance to cardiovas-
cular risk. It is not clear in the literature which index represents this imbalance and what is
their involvement with the menopausal state. The aim of this study was to evaluate HRV in
menopausal transition and post-menopausal symptoms with different intensities. This
cross-sectional study was conducted in Rio Branco, State of Acre, Brazil from October 2016
to July 2017. We used Kupperman-Blatt Menopausal Index (KMI) to measure menopausal
symptoms intensity. HRV analysis was performed based on the guidelines of the European
Society of Cardiology and the North American Society of Pacing and Electrophysiology.
HRV is lower in the group with moderate/intense menopausal symptoms compared to mild
symptoms. (RMSSD: p = 0.005, Cohen’s d = 0.53, pNN50: p = 0.0004, Cohen’s d = 0.68;
HF: p = 0.024, Cohen’s d = 0.44). There was association between HRV and KMI (RMSSD:
r = -1.248, p = 0.004; and pNN50: r = -0.615, p: 0.029) in inverse relation to the intensity of
vasomotor symptoms in women in TM. In conclusion, HRV was able to distinguish meno-
pausal symptoms, indicating reduced vagal control in women with more intense symptoms.
Introduction
The transition to menopause (TM) and postmenopausal (PM) comprise a life span related to
biological, psychological and social changes that occur in the reproductive and non-reproduc-
tive period of women. It is characterized by the presence of menopausal symptoms and reper-
cussions on different organs and systems, including cardiac autonomic regulation [1–4].
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The main menopause symptoms comprises vasomotor (hot flushes), which arise from
physiological hypoestrogenism due to progressive ovarian failure. These symptoms have been
related to the action of the sympathetic and parasympathetic nervous systems [5]. In this
sense, heart rate (HR) variability (HRV) is a non-invasive method that evaluates the autonomic
nervous system (ANS) function used as a marker of autonomic homeostasis and considered a
prognostic tool for cardiovascular morbidity and mortality [6–11].
Hypoestrogenism promotes modifications in the autonomic control of HR, inducing
changes in sympathetic and vagal regulation of the heart rhythm [12, 13]. Akiyoshi et al. [12]
demonstrated that cardiac parasympathetic function is reduced in TM and PM, which are
associated to aging and hormone level. Freedman et al. [14] and Neufeld et al. [15] demon-
strated that vasomotor symptoms are related with sympathetic predominance in the PM
period.
Hot flushes, a major expression of vasomotor symptoms, are related to cardiovascular risks
and reductions in cardiac vagal control analyzed through HRV, which increases cardiovascular
morbidity and mortality [13, 16–20]. Thurston et al. [16, 17] and De Zambotti et al. [13] sup-
ported the reduction of vagal activity associated with hot flushes, regardless of the life span,
reinforcing the development of cardiovascular complications.
Although it was documented autonomic dysfunction in the postmenopausal period via
HRV, it is not clear whether this method is able to distinguish the symptoms intensities. This
information would be extremely relevant for the medical team to better plan the treatment.
Therefore, we aimed to evaluate HRV in menopausal transition and post-menopausal symp-
toms with different intensities.
Methods
STROBE guidelines
Our investigation follows instructions from the STROBE (STrengthening the Reporting of
OBservational studies in Epidemiology) guidelines. Our study provides information of the
study setting, design, variables, participants, description of potential sources of bias, data
sources, measurement, quantitative variables description, and statistical methods.
Population study and eligibility criteria. The study population consisted of women who
attended the first consultation over 40 years old and were divided into two groups according
to their reproductive and non-reproductive period: 1) the menopausal transition group (TM,
n = 71) was characterized by irregular menstrual cycle (absence of at least two menstrual cycles
in 6 months) and presence of menopausal symptoms; 2) postmenopausal group (PM, n = 38),
characterized by absence of menstrual cycle for 12 months, as defined by the North American
Menopause Society [21, 22].
We did not include women under antidepressants, angiotensin converting enzyme (ACE)
inhibitors, beta-blockers treatment, with fever, cardiomyopathies, decompensated heart failure,
under hormone therapy, abnormal genital bleeding of unknown cause, hysterectomized,
women with no precisely menopause determination, volunteers with any type of alteration in
the ECG tracing (arrhythmias, below and / or above ST segment elevation), HR recording with
less than 95% sinus and volunteers who refused to sign the free and informed consent form.
Ethical approval and informed consent. The study was approved by the Research Ethics
Committee in Research of School of Medicine of ABC via Brazilian Platform (http://
plataformabrasil.saude.gov.br/login.jsf) (Number 1.748.393 / 2016). Informed consent was
provided to all participants. A statement from the Committee stated that the study were per-
formed in accordance with the 466/2012 resolution of the National Health Council of Decem-
ber 12nd 2012.
HRV and menopausal symptoms
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Study design and setting. This is a prospective, observational and cross-sectional study
performed at Basic Health Units Mariano Gonzaga and Maximo Diogo Magalhães, Municipal
Secretary of Health, in Rio Branco, State of Acre, Brazil from October 2016 to July 2017.
Bias. We completed all protocols under the same environments to address potential
sources of bias. HR recording was performed at the same time of the day (between 8:00 and
12:00 am) to standardize circadian influences, in a room with temperature between 22˚C and
25˚C The subjects were recommended to avoid drinking coffee and other autonomic stimulants
24 hours before the data collection and to maintain an empty bladder during HR recording.
In order to characterize the sample, reduce the unpredictability of the variables, improve
the reproducibility and physiological interpretation we measured age, mass (kg), height (m),
systolic (mmHg) and diastolic arterial pressure (mmHg), abdominal circumferences (cm) and
body mass index (BMI).
Initial assessment and experimental protocols. Firstly, all the subjects answered the
Kupperman-Blatt Menopausal Index (KMI). Subsequently, we measured baseline arterial
blood pressure and HR for 20 minutes in dorsal decubitus under spontaneous breathing.
Variables, data sources and outcome measures
HRV analysis. RR intervals were recorded through the portable RS800CX monitor with a
sampling rate of 1 kHz. The RR intervals were then transferred to the Polar Precision Perfor-
mance program (v.3.0, Polar Electro, Finland). The Polar transmitter detects heart beats in the
left ventricular muscle and transmit the signal to the computer through a wireless technology.
The software allowed the visualization and the removal of RR interval file in “txt” format.
We performed HRV analysis based on directives from the Task Force guidelines [6]. Spe-
cific details of HRV analysis have been previously documented [23, 24].
HRV was analyzed in the time (RMSSD: root-mean square of differences between adjacent
normal RR intervals, SDNN: standard deviation of all normal RR intervals) and frequency
domain (LF: low frequency band ranging from 0.04 to 0.15, HF: high frequency band ranging
from 0.15 to 0.4) in absolute units. HRV analysis also included approximate entropy (ApEn)
and the Poincare´ plot (SD1: standard deviation of the instantaneous variability of the beat-to-
beat heart rate, SD2: standard deviation of long-term continuous RR interval variability) [6].
We employed the Kubios1HRV v. 2.0 software to compute these indices [25].
The Kupperman-Blatt Menopausal Index (KMI). This index is composed of 11 sociode-
mographic and clinical questions to measure the intensity of menopausal symptoms. The
index score is categorized into mild (up to 19), moderate (between 20 and 35) and intense
(above 35) [26, 27].
Study size. The sample power test was calculated from a pilot study according to the
RMSSD. The test was based on 42.93±39.33 ms in the TM group and 25.56±14.6 ms in the PM
group with 95% confidence level, per alpha risk of 5% and beta of 80%. The sample size deter-
mined a required sample of 37 people for each group.
Statistical analysis. We completed a Shapiro-Wilk normality test to estimate the distribu-
tions. To compare HRV between PM and TM groups we applied non-paired Student t test for
parametric distributions and Mann-Whitney test for non-parametric distributions. Statistical
significance was considered at the level p<0.05. To evaluate the magnitude of differences
between groups we calculated the effect size through Cohen’s d. We considered large effect
size for values > 0.9, medium effect size for values between 0.9 and 0.5 and small effect size for
values between 0.5 and 0.25 [28].
In order to compare HRV categorized based on the magnitude of vasomotor, psychological
and somatic symptoms, we applied two way ANOVA followed by Bonferroni post test.
HRV and menopausal symptoms
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A linear regression analysis was performed in the reverse mode to determine which inde-
pendent variables (age, transition to menopause, comorbidities, linear indices in the time
domain and frequency) influenced the dependent variable (KMI).
Results
The sociodemographic and clinical profile of the 109 women evaluated are shown in Table 1.
Table 2 presents the KMI questionnaire elaborated with regard to its various components,
emphasizing upon the intensity of symptoms under vasomotor, somatic and psychological
symptoms, for both groups separately. The women showed moderate menopausal symptoms
in both groups with KMI score 23,47 (11,76) at menopausal transition group and KMI score
Table 1. Socioeconomic, demographic and clinical characteristics of elaborated according to groups menopausal transition and postmenopausal.
Variables Transition to menopause
(n:71)
Postmenopausal
(n:38)
N Mean SD N Mean SD
Age (years)� 71 45.27 3.59 38 54.16 4.52
Age of menarche (years) 71 13.27 1.36 38 13.29 1.64
Age of menopause (years) - - - 38 47.39 5.69
Body mass index (BMI) 71 28.46 5.03 38 28.31 4.95
Abdominal circumference (cm) 71 88.23 14.26 38 90.18 13.48
Systolic arterial pressure (mmHg) 71 122.18 14.74 38 124.00 14.57
Diastolic arterial pressure (mmHg) 71 84.37 16.62 38 84.47 17.66
N % N %
Race
White 10 14.1 6 15.8
Non-white 61 85.9 32 84.2
Marital status�
Single / widow / divorced 34 47.9 26 68.4
Stable union 37 52.1 12 31.6
Income a
No income / less than 1 MW 41 57.7 18 47.4
1–2 MW 28 39.4 20 52.6
� 2.1 MW 2 2.8 0 0.0
Schooling
� 8 years 45 63.4 30 78.9
> 8 years 26 36.6 8 21.1
Occupation
Employee 20 28.2 12 31.6
Not employee 51 71.8 26 68.4
Physical activity
Yes 17 23.9 9 23.7
No 54 76.1 29 76.3
Parity
0–3 45 63.4 19 50.0
� 4 26 36.6 19 50.0
Comorbidity �
Yes 6 8.5 9 23.7
No 65 91.5 29 76.3
https://doi.org/10.1371/journal.pone.0225866.t001
HRV and menopausal symptoms
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27,68 (18,57) at postmenopausal group (C = 0,282). Vasomotor symptoms are prominent in
the menopausal transition group (C = 0,007) with similar number of hot flushes (C = 0,916).
Table 3 presents HRV in menopausal transition and postmenopausal women with mild vs.
moderate/intense symptoms. We reported that RMSSD, pNN50 and HF band were signifi-
cantly decreased in the group with moderate/intense symptoms. On the other hand, no signifi-
cant differences were found for SDNN, LF band and LF/HF ratio.
We divided subjects in menopause transition and post-menopause subjects and compared
HRV indices between them. There was significant (small effect size) higher LF (ms2) values in
the menopause group (Table 4).
Table 2. Menopause symptoms and Kupperman-Blatt menopausal index (KMI) elaborated according to groups menopausal transition and postmenopausal.
Symptoms Menopause transition
(n:71)
Post-menopause
(n:38)
Mean SD Mean SD C
Vasomotor 5.01 4.36 7.26 4.63 0.007
Paraesthesia 2.39 1.90 2.47 2.10 0.039
Insomnia 2.96 2.33 3.58 2.37 0.263
Nervousness 3.18 2.28 2.97 2.39 0.089
Melancholy 1.38 1.04 1.53 1.17 0.135
Vertigo� 1.37 1.01 1.63 1.21 0.233
Weakness 1.28 1.08 1.24 1.24 0.034
Arthralgia/Myalgia 1.65 1.16 1.58 1.28 0.057
Chronic headache 2.03 1.06 1.76 1.26 0.231
Palpitation 1.48 1.11 1.29 1.11 0.171
Formication 1.18 1.16 1.13 1.09 0.044
Number hot flashes per day� 2.85 3.52 3.95 4.24 0.282
Total KMI score 23.47 11.76 27.68 18.50 0.916
KMI: Kupperman-Blatt index; C: Cohen’s d
�p<0.05.
https://doi.org/10.1371/journal.pone.0225866.t002
Table 3. HRV in menopause transition and postmenopausal women with mild and moderate/intense symptoms.
HRV indices Mild
(n:48)
Moderate/intense
(n:61)
Mean SD Mean SD C
MeanRR� 901.74 123.25 843.35 122.65 0.47
SDNN 27.49 14.18 28.85 11.06 0.1
RMSSD� 31.40 19.40 22.70 12.72 0.53
pNN50� 14.32 15.64 5.80 8.41 0.67
LFms2 351.22 320.96 287.24 293.36 0.2
LFnu� 51.02 16.11 69.44 103.76 0.24
HFms2� 440.60 530.54 247.08 291.60 0.45
HFnu� 49.52 16.46 42.92 17.72 0.38
Total 847.64 839.63 573.64 556.52 0.38
LF/HF� 1.63 1.78 2.02 1.59 0.23
SDNN: Standard deviation of all normal RR intervals; RMSSD: root-mean square of differences between adjacent normal RR intervals; pNN50: percentage of adjacent
RR intervals with a difference of duration greater than 50ms; LF: Low frequency; HF: High frequency; ms: milliseconds; mod/int: moderate and intense symptoms; C:
Cohen’s d; SD: Standard deviation
�p<0.05.
https://doi.org/10.1371/journal.pone.0225866.t003
HRV and menopausal symptoms
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HRV was also categorizing based on the magnitude of vasomotor, psychological and
somatic symptoms. In Table 5 we noted reduced values of SDNN, LFms2, HFms2, total power
and LF/HF ratio in the somatic symptom compared to vasomotor and psychologic symptoms.
The interference analysis is demonstrated in Table 6 through a linear regression model
between menopausal symptoms and independent variables. Regression analysis revealed sig-
nificant interaction of menopause symptoms with SDNN, RMSSD, pNN50, HF and LF indi-
ces. It was verified that the model covered 21.4% of the factors that influence the KMI.
Discussion
This investigation was undertaken to evaluate HRV in menopausal transition and post-meno-
pausal symptoms with different intensities. We reported that: 1) menopausal transition and
post-menopausal women with more intense symptoms showed reduced HRV; 2) somatic
Table 4. HRV in menopause transition and post-menopause subjects.
HRV indices Menopause transition
(n: 71)
Post-menopause
(n:38)
Mean SD Mean SD C
MeanRR 857.44 113.37 889.97 146.84 0.24
SDNN 26.43 13.25 21.75 11.19 0.38
RMSSD 27.72 17.23 24.07 15.13 0.22
pNN50 10.05 13.05 8.55 12.53 0.11
LFms2� 357.04 313.48 233.13 281.03 0.41
LFnu 65.32 97.19 53.60 18.84 0.16
HFms2 371.95 471.88 261.73 307.28 0.27
HFnu 45.92 16.59 46.27 18.82 0.01
Total 775.53 778.44 539.21 526.53 0.35
LF/HF 1.96 1.88 1.57 1.16 0.24
SDNN: Standard deviation of all normal RR intervals; RMSSD: root-mean square of differences between adjacent normal RR intervals; pNN50: percentage of adjacent
RR intervals with a difference of duration greater than 50ms; LF: Low frequency; HF: High frequency; ms: milliseconds; C: Cohen’s d; SD: Standard deviation
�p<0.05.
https://doi.org/10.1371/journal.pone.0225866.t004
Table 5. HRV categorizing based on the magnitude of vasomotor, psychological and somatic symptoms.
HRV indices Vasomotor Somatic Psychologic
Mean SD Mean SD Mean SD
MeanRR 900.84 119.94 931.25 259.72 904.88 168.60
SDNN 26.25� 15.02 18.10 15.69 27.73� 16.30
RMSSD 29.82 20.71 25.25 22.69 28.46 16.64
NN50 171.63 240.85 128.00 181.01 171.00 182.23
pNN50 12.20 16.03 10.15 14.35 13.10 13.40
LFms2 332.73� 337.37 125.00 162.63 476.22� 454.84
HFms2 416.66� 587.58 220.50 280.71 396.77� 428.20
Total 776.72� 932.85 361.35 463.86 942.33� 927.39
LF/HF 1.68� 1.88 0.504 0.097 1.32� 0.60
SDNN: Standard deviation of all normal RR intervals; RMSSD: root-mean square of differences between adjacent normal RR intervals; pNN50: percentage of adjacent
RR intervals with a difference of duration greater than 50ms; LF: Low frequency; HF: High frequency; ms: milliseconds; SD: Standard deviation.
�p<0.05 vs. Somatic.
https://doi.org/10.1371/journal.pone.0225866.t005
HRV and menopausal symptoms
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symptoms are suggested to be the main variable related to HRV impairment; 3) time and fre-
quency domain HRV indices presented significant interaction with menopausal symptoms.
Regardless of the menopausal status, the number of hotflushes and the intensity of meno-
pausal symptoms did not show statistical significance. Both groups present moderate to severe
menopausal symptoms, and these findings are in agreement with other studies [29–31].
HRV indices represents cardiac autonomic behavior and have been related to menopausal
symptoms, mainly vasomotor symptoms and their imbalance to cardiovascular risk [29–31].
In the literature, it is not clear which index represents this imbalance and the involvement of
the menopausal state.
We reported significant increased values of RMSSD, pNN50 and HF in the mild symptom
group compared to the moderate/intense symptoms group. This result evidences the mixed repre-
sentation of the sympathetic and parasympathetic autonomic nervous system [12] during this
period of the woman’s life. The linear regression analysis showed that the lower the HRV indices
the higher the symptoms, suggesting vagal withdrawal and concomitant sympathetic activation in
women with more intense symptoms. Although previous studies do not support the LF for auto-
nomic regulation, other evidences provide support for this HRV index [11, 32–34].
Previous studies indicated sympathetic activation during hot flushes [29, 30]. Vagal afferent
stimulation leads to reflex of vagal efferent excitation and sympathetic efferent inhibition [35].
Attributing this fact only to the LF renders ambiguous interpretation, since this linear index
represents a mixture of sympathetic and parasympathetic control, evidencing a possible para-
sympathetic withdrawal and concomitant sympathetic activation, besides the description of its
relation with the baroreflex function [33, 34].
The clinical representation of the LF index arouses controversial interest according to pre-
vious evidences [11, 32]. Some authors suggest that it represents a sympathetic activation
index [15, 36] however, others described that LF reflects a complex interaction between
Table 6. Influence of age, menopausal symptoms and life span of women in the menopause transition and postmenopausal phase.
Variable β CI (95%) p r2 adjusted
Input model�
Age (years) -0.273 -0.969 a 0.422 0.437
0.229Transition to menopause -7.647 -15.794 a 0.499 0.065
Comorbities -5.31 -13.475 a 2.856 0.2
SDNN (ms) 1.957 0.613 a 3.302 0.005
RMSSD (ms) -1.182 -2.077 a -0.287 0.01
pNN50 (%) -0.649 -1.211 a -0.087 0.024
LF (ms2) -0.03 -0.058 a -0.003 0.03
HF (ms2) 0.017 -0.001 a 0.035 0.069
LF/HF (-) -0.381 -2.143 a 1.382 0.669
Final Model
Transition to menopause -6.102 -11.626 a -0.578 0.031
0.214SDNN (ms) 2.069 0.747 a 3.391 0.002
RMSSD (ms) -1.248 -2.096 a -0.401 0.004
pNN50 (%) -0.615 -1.165 a -0.065 0.029
LF (ms2) -0.035 -0.061 a -0.008 0.011
HF (ms2) 0.018 0 a 0.035 0.049
� Reverse-mode linear regression analysis between the KMI and independent variables
SDNN: Standard deviation of all normal RR intervals; rMSSD: root-mean square of differences between adjacent normal RR intervals; pNN50: percentage of adjacent
RR intervals with a difference of duration greater than 50ms; LF: Low frequency; HF: High frequency.
https://doi.org/10.1371/journal.pone.0225866.t006
HRV and menopausal symptoms
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sympathetic and parasympathetic functions. Other factors such as baroreflex control and
direct central rhythmic influences [33, 35] are still not totally identified at low frequency.
The LF/HF ratio is debatable because it does not precisely quantify the sympathovagal bal-
ance, in relation to the health-disease process [33, 34] in cardiovascular disease. It is known
that parasympathetic activation represents at least 50% of LF and sympathetic activity approxi-
mately 25% and the LF is influenced by the mechanical effects of breath [34]. In our study, the
LF/HF ratio remained similar regardless of menopausal status.
The association between HRV and the intensity of menopausal symptoms in our study
expressed the parasympathetic behavior in the RMSSD and pNN50 indices of HRV, where the
higher the intensity of menopausal symptoms the lower the parasympathetic influence, sug-
gesting a decrease in vagal tone with increasing symptom intensity. This results is in agreement
with Thurston et al. [16, 17] and De Zambotti et al. [13], which demonstrated a reduction in
vagal activity associated with hot flushes, the main menopausal symptom.
Time domain indices are evaluated with statistical calculations of RR intervals and measure
the individual cardiac cycle length dispersion around its mean, including the SDNN. This
index is considered a marker of the total power (variance) of the HRV and expresses the long-
term component responsible for the variability in the period of registration of the HR. There-
fore, it is a global index that reflects both sympathetic and parasympathetic modulation [6, 8].
In our study, the SDNN index maintained a proportional relation to the intensity of meno-
pausal symptoms.
In the frequency domain, the HF was increased in women with mild symptoms compared
to moderate/intense symptoms, representing higher parasympathetic control in the mild
symptoms groups. These results contradict the findings support Thurston et al. [16] and De
Zambotti et al. [13] who recorded acute decreases in HF associated with hot flushes, compati-
ble with vagal withdrawal. Moreover, when we evaluated the RMSSD and PNN50 indices,
which represent the parasympathetic HR modulation, they were also decreased in women with
moderate/intense symptoms and expressed a significant decrease in the parasympathetic pre-
dominance with the increase in the intensity of the vasomotor symptoms (presence and fre-
quency of the hot flushes).
The HRV analysis reflects prediction of the internal functions of the body, both in normal
and pathological conditions, identifying physiological changes in the organism and the pres-
ence of diseases [8, 37]. The action of the ANS on the physiological mechanism of vasomotor
symptoms is pertinent thematic, since its neuroendocrine and metabolic functioning is still
uncertain scientific literature [14, 38].
In this context, when categorizing based on the magnitude of vasomotor, psychological and
somatic symptoms in order to better delineate the role of autonomic modulation, we suggest
that somatic symptoms have higher impact on HRV. With this in mind, previous studies have
already raised the association between somatic disorders and HRV [39, 40]. Taken together,
the literature support the involvement of somatic symptoms in reduced HRV in post-meno-
pausal women.
The limitations of the study consist in a transversal design and can not establish cause and
effect relationships with vasomotor symptoms and HRV. The age group is significantly differ-
ent between two groups and HRV is an age dependent parameter [41]. However, age is a vari-
able related to menopause transition, which does not make possible to provide subjects with
similar ages in similar menopause period. In addition, instruments that measure menopausal
symptoms, such as KMI, are composed of somatic and psychological clinical manifestations,
based on reports. In this way, the physiological reliability of measurement instruments is
debatable, since all are passive of failures because it contains a certain margin of error, even
after reliability and validity tests.
HRV and menopausal symptoms
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Our results provide relevant information for the clinical team that deal with menopausal
transition and postmenopausal women. Understanding that HRV helps to distinguish meno-
pausal symptoms will aid to plan treatments for this specific population.
Conclusion
We evidenced that HRV was decreased in menopausal transition and post-menopausal
women with more intense symptoms. The findings suggest that somatic symptoms have a
close relationship with HRV. Moreover, HRV presented significant association with meno-
pausal transition and post-menopausal symptoms. Our data suggest that HRV may be able to
detect the intensity of symptoms menopausal and menopausal transition.
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